Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey

dc.contributor.author	Levy, A
dc.contributor.author	Hendriks, L
dc.contributor.author	Le Pechoux, C
dc.contributor.author	Falk, Sally
dc.contributor.author	Besse, B
dc.contributor.author	Novello, S
dc.contributor.author	Dingemans, A
dc.contributor.author	Hasan, B
dc.contributor.author	Reck, M
dc.contributor.author	Berghmans, T
dc.contributor.author	Faivre-Finn, Corinne
dc.date.accessioned	2019-09-11T09:09:23Z
dc.date.available	2019-09-11T09:09:23Z
dc.date.issued	2019	en
dc.identifier.citation	Levy A, Hendriks LEL, Le Péchoux C, Falk S, Besse B, Novello S, et al. Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey. Radiother Oncol. 2019;133:S402-S3.	en
dc.identifier.doi	10.1016/S0167-8140(19)31199-5	en
dc.identifier.uri	http://hdl.handle.net/10541/622075
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1016/S0167-8140(19)31199-5	en
dc.title	Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey	en
dc.type	Meetings and Proceedings	en
dc.contributor.department	Gustave Roussy, Radiation Oncology, Villejuif, France	en
dc.identifier.journal	Radiotherapy and Oncology	en
dc.description.note		en]
refterms.dateFOA	2019-09-21T09:20:48Z

Name:

PIIS0167814019311995.pdf

Size:

277.4Kb

Format:

PDF

Description:

Full text, Open Access article